OncoMatch

OncoMatch/Clinical Trials/NCT04774718

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Is NCT04774718 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Alectinib for alk fusion-positive solid or cns tumors.

Phase 1/2RecruitingHoffmann-La RocheNCT04774718Data as of May 2026

Treatment: AlectinibThis study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: ALK fusion

Prior therapy

Min 1 prior line

Must have received: any prior anti-cancer therapy

prior treatment proven to be ineffective (i.e. relapsed or refractory), or for whom there is no satisfactory standard treatment available

Cannot have received: ALK inhibitor

prior use of ALK inhibitors

Cannot have received: stem cell infusion

stem cell infusions as defined by the protocol

Cannot have received: investigational therapy

Treatment with investigational therapy 28 days prior to initiation of study drug

Lab requirements

Blood counts

Adequate bone marrow function as defined by the protocol within at least 28 days prior to initiation of study drug

Kidney function

Kidney disease as defined by the protocol excluded

Liver function

Liver disease as defined by the protocol excluded

Adequate bone marrow function as defined by the protocol within at least 28 days prior to initiation of study drug; Liver or kidney disease as defined by the protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Lucile Packard Children's Hospital · Palo Alto, California
  • Johns Hopkins All Children's Hospital · St. Petersburg, Florida
  • University of Michigan, C.S. Mott Children's Hospital · Ann Arbor, Michigan
  • Children's Minnesota · Minneapolis, Minnesota
  • Memorial Sloan Kettering Cancer Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify